In summary, our data indicates that combination of inhibitors targeting IGFR and the PI3K/Akt/mTOR pathway can improve treatment efficacy for HCC in vitro and in a xenograft mouse model in vivo. The gene discussed is MTOR; the disease is hepatocellular carcinoma.